Compare Ascendis Pharma A/S (ASND) vs Vanguard Total Bond Market Index Fund ETF (BND) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Vanguard Total Bond Market Index Fund ETF — how do they compare? Ascendis Pharma A/S trades at $263 (market cap $17.74B), while Vanguard Total Bond Market Index Fund ETF trades at $72.53. The key difference: Ascendis Pharma A/S is trading nearer its 52-week high, Vanguard Total Bond Market Index Fund ETF nearer its low. Which is the better fit depends on your goals.
| ASND | BND | |
|---|---|---|
Market Cap | $17.74B | — |
Sector | Health | — |
52-Week High | $277.18 | $75.17 |
52-Week Low | $163.32 | $72.45 |
Enterprise Value | $18.11B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
BND trades at $72.77, down 0.08% on the day, with a bearish technical signal driven by moving averages. Recent news highlights its role as a core bond ETF for stability and income, with comparisons to peers like iShares IGIB focusing on yield and cost advantages. The fund's dividend history shows consistent payouts, supporting its appeal for income-focused investors amid market volatility.
The outlook for BND is cautious due to bearish technicals and interest rate risks, but its low-cost, diversified bond exposure offers defensive appeal. Key risks include duration sensitivity to Fed hikes, while institutional inflows signal confidence in fixed income. Investors should weigh yield stability against potential price declines if rates rise further.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Vanguard Total Bond Market Index Fund ETF
This index measures the performance of a wide spectrum of public, investment-grade, taxable, fixed income securities in the US, including government, corporate, and international dollar-denominated bonds, as well as mortgage-backed and asset-backed securities-all with maturities of more than 1 year. All of the fund's investments will be selected through the sampling process, and at least 80% of its assets will be invested in bonds held in the index.
Read more on BND →
